

June 06, 2008

vasopharm's trauma compound VAS203 successfully completes clinical phase Ib study

Wuerzburg, Germany – June 06, 2008

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced positive results of a phase Ib study with its antipterin VAS203 which is a new allosteric NOS modulator. The placebo-controlled, double blind study was performed in order to investigate safety, tolerability and pharmacokinetics of VAS203 after repetitive dosing. The drug was given via a daily infusion up to three consecutive days and was found to be safe and well tolerated. The same treatment regimen is considered for the upcoming clinical phase II trial.

About vasopharm:

vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. The company is focused on the development of therapeutics which permits modulating the bioavailability of biological NO, by addressing the entire NO/cGMP signal cascade and its functional counterpart NOX. vasopharm's drug candidate VAS203 represents a completely new class of NOS modulators targeting cerebral vessels and cerebral tissue, thus preventing life threatening rises in intracranial pressure.
